- Home
- XAIR
XAIR
Beyond Air Inc.
as 05-10-2024 4:00pm EST
Beyond Air Inc is a clinical-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | GARDEN CITY |
| Market Cap: | 52.8M | IPO Year: | N/A |
| Target Price: | $10.75 | AVG Volume (30 days): | 303.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.13 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.06 - $6.36 | Next Earning Date: | 06-20-2024 |
| Revenue: | $689,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 824.40% |
Share on Social Networks:
Stock Insider Trading Activity of Beyond Air Inc. (XAIR)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Myers Jeff Lynn | XAIR | Chief Medical Officer | Dec 27 '23 | Sell | $2.21 | 3,423 | $7,578.52 | 46,577 | SEC Form 4 |
| Lisi Steven A. | XAIR | CEO and Chairman of the Board | Dec 18 '23 | Buy | $1.63 | 77,775 | $126,796.58 | 1,536,471 | SEC Form 4 |
Latest Beyond Air Inc. News
XAIR Breaking Stock News: Dive into XAIR Ticker-Specific Updates for Smart Investing
GlobeNewswire
11 days ago
Beyond Cancer Selected to Present on the Clinical Development of Ultra-High Concentration Nitric Oxide (UNO) Therapy at the 2024 American Society of Clinical Oncology Annual Meeting
GlobeNewswire
2 months ago
Beyond Air® Announces Pricing of $16.0 Million Registered Direct Offering of Common Stock and Warrants
GlobeNewswire
3 months ago
Beyond Air® Reports Financial Results for Third Quarter of Fiscal Year 2024
Simply Wall St.
3 months ago
After losing 76% in the past year, Atara Biotherapeutics, Inc. (NASDAQ:ATRA) institutional owners must be relieved by the recent gain
Business Wire
3 months ago
Atara Biotherapeutics and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel® Data in The Lancet Oncology
Simply Wall St.
3 months ago
Will Connect Biopharma Holdings (NASDAQ:CNTB) Spend Its Cash Wisely?
PR Newswire
4 months ago
Vanda Pharmaceuticals Announces a U.S. Patent Allowance for PONVORY® (ponesimod) in the U.S.
GlobeNewswire
4 months ago